Datapoint: FDA Approves Celltrion’s Humira Biosimilar

The FDA last week approved Celltrion Healthcare’s high-concentration Humira biosimilar, Yuflyma, for eight of Humira’s indications. The company expects to launch the drug, which will be available as both a pre-filled syringe and autoinjector, in July, alongside several other Humira copies from other drugmakers. Celltrion is also seeking interchangeability status from the FDA, and anticipates a decision in the fourth quarter of 2024. The first Humira biosimilar, Amgen’s Amjevita, launched Jan. 31. For the treatment of rheumatoid arthritis, the Amjevita autoinjector currently holds covered or better status for 67% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 5/26/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today